MedTrace Logo

Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation

NCT03689075 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-04-13

No results posted yet for this study

Summary

Study to compare once-daily extended release tacrolimus versus twice-daily immediate release tacrolimus following renal allograft failure to reduce the risk of allosensitisation

Conditions

  • Kidney Transplant Failure
  • Allosensitization
  • Immunosuppression

Interventions

DRUG

Envarsus Oral Product

Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation

Sponsors & Collaborators

  • Imperial College Healthcare NHS Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2024-06-27
Completion
2025-02-25

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03689075 on ClinicalTrials.gov